Pregabalin Capsule
Product Images NDC 63629-8239

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 63629-8239). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl636298239)

Label for Pregabalin Capsules USP, 225 mg, from Bryant Ranch Prepack. The label includes the NDC number 63629-8239-01 and indicates the package contains 30 capsules. Storage instructions and safety warnings are printed along with a barcode and the BRP Pharmaceuticals logo.*

FDA Label Image

Label (Lbl6362982392)

Pregabalin 225 mg capsule label from Bryant Ranch Prepack showing it is an orange capsule. The label states it compares to Lyrica 225 mg capsule by ScieGen Pharmaceuticals, Inc. It includes storage instructions (20°-25°C), a barcode, lot number 1523487, and the NDC 63629-8239-1 with a package quantity of 30 capsules. The label indicates prescription use (Rx Only).*

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line graph illustrating the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at doses of 200 mg, 100 mg, 25 mg three times a day, and placebo. The x-axis shows percent improvement in pain; the y-axis shows the percent of patients improved. The graph compares efficacy across different dosages and placebo.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A line chart comparing percent of patients improved versus percent improvement in pain from baseline, showing two treatment groups: Pregabalin 100 mg three times a day and placebo. The graph plots cumulative patient response rates across varying thresholds of pain improvement.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline for Pregabalin at doses of 75 mg, 150 mg, 300 mg taken twice a day, and placebo. The graph shows multiple curves plotting patient response across a range of pain improvement percentages from 0 to 100.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

A line graph comparing the percentage of patients improved at various levels of percent improvement in pain from baseline. It includes data for Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo groups, with percent improved on the vertical axis and percent pain improvement on the horizontal axis.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line graph showing percent of patients improved on the vertical axis versus percent improvement in pain from baseline on the horizontal axis. It compares three groups: Pregabalin 100 mg three times a day (dashed line), Pregabalin 50 mg three times a day (solid line), and placebo (dotted line). Vertical reference lines are drawn at approximately 30% and 50% pain improvement.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

A bar chart comparing responder rates (%) in two clinical studies, Study E1 and Study E3. The x-axis shows different treatment groups with doses of pregabalin (50 mg/day to 600 mg/day) and placebo. The y-axis represents responder rates from 0% to 60%. Study E1 shows increasing responder rates with higher pregabalin doses, peaking at 51% for 600 mg/day. Study E3 shows 43% responder rate for 300 mg/day and 49% for 600 mg/day. Statistically significant differences versus placebo are marked with an asterisk.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A line graph depicting seizure reduction as median percent change from baseline versus dose in mg/day. Four study groups labeled Study E1 BD, Study E2 TID, Study E3 BD, and Study E3 TID are represented with different markers. Statistically significant p-values are noted along the lines indicating dose-response effects.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line graph comparing the percent of patients improved in pain relative to baseline across four groups: Pregabalin 800 mg daily dose, Pregabalin 450 mg daily dose, Pregabalin 300 mg daily dose, and placebo. The x-axis shows percent improvement in pain from baseline, and the y-axis shows the percent of patients improved. Four lines represent each treatment group, illustrating trends in patient improvement over a range of percent improvements.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A Kaplan-Meier survival curve chart depicting the estimated percentage of subjects without LTR (loss to response) over 180 days. Two lines are shown: a solid line for Pregabalin and a dashed line for Placebo, indicating higher survival without LTR in the Pregabalin group compared to Placebo.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A line graph comparing the percentage of subjects improved over percent improvement from baseline to week 12 BOCF for Pregabalin 225 mg and placebo. The x-axis represents percent improvement from baseline, ranging from 0 to 100%, and the y-axis represents the percent of subjects improved, ranging from 0 to 100%. The solid line indicates Pregabalin and the dotted line indicates placebo.*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line graph comparing the percent of subjects improved with Pregabalin versus placebo. The x-axis represents percent improved from baseline to week 16 BOCF, ranging from >0% to 100%. The y-axis represents the percent of subjects improved, ranging from 0% to 100%. The solid line represents Pregabalin, and the dashed line represents placebo, showing consistently higher improvement with Pregabalin across improvement percentages.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

A formula for calculating creatinine clearance (CLcr) based on age, weight, and serum creatinine levels, with an adjustment factor for female patients. This calculation is often used to assess kidney function.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure of Pregabalin showing its molecular configuration with amino and carboxyl functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.